Search

everythinglearnresearchcommunity

for

Search:↓

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Ritlecitinib was generally well tolerated in children with alopecia areata.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.

A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Nilotinib can cause generalized keratosis pilaris.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

Drug repurposing is a cost-effective way to find new uses for existing drugs, speeding up treatment development.

Natural products can help overcome cancer drug resistance.

New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.

Finding new uses for existing drugs is promising and can lead to safer, more effective medicines.

Certain cancer drugs are strongly linked to nerve damage, requiring close monitoring and early treatment.

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.

Chemotherapy can cause skin issues and hair loss, and this guide explains how to manage them.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.

Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.

Tofacitinib might be used to treat hair loss.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.